The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated to the combination shot,

standalone flu vaccine called tNIV. Robert Walker, Novavax’s chief medical officer, said that the FDA “satisfactorily addressed all clinical hold issues.” Walker confirmed that trial activities will resume as soon as possible. Novavax’s upcoming ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the vaccine and a reported adverse neurological event. This decision enables Novavax to resume late-stage testing.